PET/CT and breast cancer

Maria Picchio, Cristina Messa, Barbara Zangheri, Claudio Landoni, Luigi Gianolli, Ferruccio Fazio

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

During the last decade, the application of positron emission tomography (PET) has remarkably improved the management of cancer patients. The radiotracer most widely used in clinical practice is the glucose analogue 2-[ 18F]-fluoro-2-deoxy-D-glucose (FDG). FDG-PET is showing increasing usefulness in the distinction between malignant and benign lesions, in disease staging, re-staging and therapy planning. Due to the lack of precise anatomic landmarks, PET may present limitations in lesion localization. In contrast, PET/computed tomography (CT), by directly combining functional and morphological aspects, provides more reliable anatomical details. The main advantage of combined PET/CT imaging is, in fact, its ability to accurately correlate abnormal metabolic changes detected on PET imaging to anatomic structures defined at CT imaging (Townsend 2001). With this chapter, the impact in breast cancer diagnosis of PET/CT will be evaluated and compared with PET alone, visually correlated with morphologic imaging obtained in a separate session.

Original languageEnglish
Title of host publicationBreast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options
PublisherSpringer Berlin Heidelberg
Pages217-226
Number of pages10
ISBN (Print)9783540367802
DOIs
Publication statusPublished - 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'PET/CT and breast cancer'. Together they form a unique fingerprint.

Cite this